Rheumatoid arthritis in Latin America: the importance of an early diagnosis by Licia Maria Henrique da Mota et al.
REVIEWARTICLE
Rheumatoid arthritis in Latin America: the importance
of an early diagnosis
Licia Maria Henrique da Mota1 & Claiton Viegas Brenol2 &
Penelope Palominos3 & Geraldo da Rocha Castelar Pinheiro4
Received: 23 February 2015 /Revised: 10 April 2015 /Accepted: 17 May 2015 /Published online: 25 July 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract The generalization of the early rheumatoid arthritis
(ERA) concept and the existence of a window of therapeutic
opportunity—a time span in which the institution of a proper
therapeutic method for the disease would determine clinical
improvement—have set the notion that early diagnosis and
treatment may modify the course of the disease. Although in
several regions of the world, especially in North America and
Europe, since the year 2000, a significant reduction in diag-
nostic delay was observed in cohorts of patients with rheuma-
toid arthritis (RA), probably reflecting a stronger awareness of
the importance of early diagnosis, this is not a reality in Latin
America (LA). LA is a region of great economic inequality,
with disparities in access to the public healthcare system and
limited access to private medicine, being widely difficult to
obtain a specialized medical evaluation in both scenarios. This
paper aims to briefly review the main difficulties in the
management of ERA in LA, based on the review of the liter-
ature, on the evaluation of a survey conducted among 214
rheumatologists of LA, members of Pan-American League
of Associations for Rheumatology (PANLAR) and the expe-
rience of the authors. The paper also aims to propose solutions
to the difficulties in managing ERA in LA.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune, chronic inflam-
matory disease characterized by joint swelling, joint tender-
ness, and destruction of the synovial joints that can lead to
severe disability and premature mortality. RA affects between
0.5 and 1 % of the general population, mainly during their
working age, affecting, thus, the functional capacity, with
great economic burden to the individual and the society [1].
In the last decades, there was a clear evolution in knowl-
edge about physiopathology of the disease, resulting in chang-
es in its approach and treatment. The association between
symptom duration and RA persistence is not linear, suggesting
the presence of a confined period in which RA is more sus-
ceptible to treatment [2].
Early RA (ERA) is defined as the diagnosis given in the first
weeks or months of joint symptoms or signs. The generalization
of the ERA concept and the existence of a window of therapeutic
opportunity—a time span in which the institution of a proper
therapeutic method for the disease would determine clinical im-
provement—have set the notion that early diagnosis and treat-
ment may modify the course of the disease [3].
Currently, evaluating a patient with articular symptoms in the
first possible opportunity is aimed at, and the definition of the
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RA’s early stage comprises the first weeks or months of symp-
toms (generally less than 12 months), the first 12 weeks of man-
ifestations with very early rheumatoid arthritis (VERA) standing
out as a critical period. Those patients with more than 12 weeks
and less than 12 months of articular symptoms are included in
what is known as late early rheumatoid arthritis (LERA) [4].
Concomitantly, laboratory and imaging methods were im-
proved or developed, contributing to an earlier diagnosis and
determination of prognostic for early RA [5]. In the last two
decades, RA’s treatment has undergone intense changes,
reflecting both the modification of the therapeutic approach
paradigm and the introduction of new classes of disease-
modifying anti-rheumatic drugs (DMARDs), including bio-
logical response modifiers (biological therapy) [6].
In this context, early arthritis recognition clinics (EARC)
and ERA clinics have been established in some countries in
recent decades, in order to receive early and offer appropriate
treatment for patients within the first months of disease evo-
lution, including medical follow-up by the rheumatologist
and, ideally, multidisciplinary care [7].
Despite these progresses, it is well known that the limiting
factor to a good therapeutic response is still the delay in diag-
nosis and in the institution of the adequate treatment, as well
as the difficulty in handling the medication during the patient’s
follow-up [8].
Although in several regions of the world, especially in
North America and Europe, since the year 2000, a significant
reduction in diagnostic delay was observed in cohorts of pa-
tients with RA, probably reflecting a stronger awareness of the
importance of early diagnosis, this is not a reality in Latin
America (LA) [9–12].
LA and the Caribbean, a rapidly growing region with al-
most 600 million inhabitants composed of Mexico, Central
and South America, and the islands of the Caribbean, is one
of the most unequal regions in the world, according to the
Economic Commission for Latin America and the Caribbean
(United Nations) [13, 14]. People from different LA countries
have little access to private medicine and disparities in access
to the public healthcare system, with widespread difficulty to
obtain specialized medical attention in both.
This paper aims to briefly review themain difficulties in the
management of ERA in LA, based on the review of the liter-
ature, the evaluation of a survey conducted among Latin
American rheumatologists members of Pan-American
League of Associations for Rheumatology ) and the experi-
ence of the authors. The paper also aims to propose solutions
to the difficulties in managing ERA in LA.
Materials and methods
We searched PubMed, Lilacs (Latin American and Caribbean
Literature on Health Sciences), and Scielo (Scientific
Electronic Library Online) using terms related to early arthritis
and, in PubMed, combining them with country names or re-
gional names related to Latin American and the Caribbean
Islands. The search strategy for PubMed was: (early arthritis
OR recent onset arthritis) AND (BLatin America^ OR
BCentral America^ OR BSouth America^ OR BCaribbean^
OR BArgentina^ OR BBolivia^ OR BBrazil^ OR BChile^
OR BColombia^ OR BCosta Rica^ OR BCuba^ OR
BDominican Republic^ OR BEcuador^ OR BEl Salvador^
OR BGuatemala^ OR BHaiti^ OR BHonduras^ OR
BMexico^ OR BNicaragua^ OR BPanama^ OR BParaguai^
OR BPeru^ OR BUruguay^ OR BVenezuela^). In Lilacs, we
preceded two searches, using the terms Bearly arthritis^ and
Bearly rheumatoid arthritis.^ To search through Scielo, we
used the terms Bearly arthritis^ (without quotes) and Brecent
onset arthritis.^ Articles were selected when they approached
early arthritis clinic or management of early arthritis in Latin
America and the Caribbean.
Aiming to know the panorama of the difficulties relating to
the management of ERA in LA, a survey was conducted
among members of PANLAR. The questionnaire was
forwarded by e-mail to all members of PANLAR, containing,
among other evaluations, 20 specific questions about ERA.
Several themes were addressed, including the existence or not
of ERA clinics or EARC in the region (and the country), the
definition of ERA (duration of symptoms), the system of ref-
erence from basic assistance, and the main difficulties for ac-
cess of patients to diagnostic and therapeutic management. It
was also requested from rheumatologists possible solutions to
the problems raised.
Some of the questions were multiple choice, while others
demanded detailed answers. The questionnaire is available as
Appendix 1.
Results
A total of 438 articles were identified through the online
search: 304 in PubMed, 33 in Lilacs, and 106 in Scielo.
Some of them were excluded as duplicates and most
were excluded after screening title. Around 50 articles
were selected to full-text reading and 13 were used as
references for this paper.
Two hundred and fourteen rheumatologists, from dif-
ferent LA countries, answered the survey. Table 1 sum-
marizes the responses of Latin American rheumatologists
to multiple-choice questions. Table 2 present aspects of
the current reality found on the Latin American coun-
tries, listing the challenges and proposed solutions for
resolving the difficulties observed, based on the interpre-
tation of the questionnaire applied (detailed answers) re-
garding the importance of the early diagnosis of RA in
this region.
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Table 1 Summary of the responses of rheumatologists to multiple-
choice questions to know the panorama of the difficulties relating to the
management of ERA in LA
Early rheumatoid arthritis scenario in Latino America
















In established RA clinic 37 (52.9)
Other 53 (38.41)




<1 year 10 (13.7)
Between 1 to 3 years 22 (13.14)
Between 3 to 5 years 17 (23.29)
Between 5 to 10 years 20 (27.4)






Less than 12 weeks 81 (41.75)
Less than 1 year 90 (46.39)
Less than 2 years 23 (11.86)










































Occupational therapists 31 (17.03)
Administrative staff 25 (13.74)
Other 30 (16.48)
How is the access
of the patients
to ERA clinic?







More than one above 52 (26.53)
Other 8 (4.08)


















of quality of life














Synthetic DMARDs 179 (87)




Once in a month 57 (29.23)
Every 3 months 99 (50.77)
Every 6 months 12 (6.15)
Once in a year 4 (2.05)
Other 23 (11.79)
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Table 2 The importance of early diagnosis of rheumatoid arthritis—current reality, challenges, and proposed solutions
Current reality Challenges Proposed solutions
- There are few structured clinics for screening
(capitation?) and follow-up of patients in the
early phase of arthritis or RA
Creation/establishment of clinics with
appropriate structure to receive early
on, diagnose and treat early arthritis,
both in public or private services
- Establishment of guidelines (and guides) for the
implementation of early arthritis clinics in each
service (by the local rheumatology associations
basing themselves on successful experiences
on the region itself)
- Awareness of the population, health managers,
and government on the importance of the early
diagnosis and the existence of specific structures
for diagnosis and follow-up
- Lack of medical professionals
(rheumatologists) on the existing clinics
- Allocate rheumatologist to outpatient early
arthritis or early rheumatoid arthritis clinics
- Establish healthcare policies, on public and
private services, that recognize the importance
of allocating rheumatologists in reference units
to diagnose and follow-up on early arthritis;
- Continuing medical education ofrheumatologists
and engagement in early RA clinics
- Shortage of other healthcare professionals
(nurses, occupational therapists,
physiotherapists, physical educators,
psychologists, social workers, nutritionist)
and supporting staff (secretaries) at the
existing clinics
- Designate healthcare professionals of
correlate
areas for the care of patients with early
arthritis or early RA
- Establishment, on RA patients’ follow-up
protocols, of the importance of multidisciplinary
follow-up
- Engaging of other professionals for patient
follow-up
- Patients’ difficulty of access to arthritis clinics
or early arthritis clinics, both on public and
private services
- Patient lateness in seeking health assistance
*Geographical factors (great distances—
patients that reside in rural areas, far away
from centers where there are
rheumatologists)
*Cultural factors (fear of the diagnosis, belief in
a Bserious and incurable disease^)
*Social and economical factors (lack of
resources for transportation or access to the
doctor on the private system)
*Self-medication (frequent use, with free
access, and no prescription, of anti-
inflammatory drugs and corticosteroids)
*Delay on the referral from other specialists
(general practitioners, orthopedists)
*Inexistence of an adequate reference/counter
reference system
*Lack of vacancies for the appointment of new
cases
- Optimize patients’ access to reference centers
for diagnosis and treatment of early RA
- Reducing the time between the onset of
symptoms and the assessment by the
rheumatologist
- Improve the level of knowledge on RA of
the general practitioner and of other
correlated specialist
- Educational campaigns for the patient
(information on the alert symptoms of RA and on
the importance of the early diagnosis/treatment)
- Education and training of general practitioners
and orthopedists (adequate training of general
practitioners, general internists, and allied health
professionals in articular examination and RA
symptoms and the creation of EAC or areas within
rheumatology units to provide care for patients
referred early in the course of their disease)
- Inclusion of information on arthritis on the
medical course (graduation)
- Establishment of a efficient system of reference/
counter reference that allows the referral of a
patient by the general practitioners or orthopedist
in a timely fashion, with a posterior referral to
the primary health care unit, after controlling
the disease
– Difficulties to diagnose RA
– Restricted general access to additional tests
(such as inflammatory activity tests,
rheumatoid factor and ACPA) and some
image exams (ultrasonography and magnetic
resonance imaging) on public services, and
high cost on private services
– Lack of diagnosis protocols
- Broaden the access to additional tests
eventually necessary for the differential
diagnosis, both on public and private
healthcare services
- Establishment of local protocols (regional
associations of rheumatology, hospital services
protocols) for early diagnosis of RA
- Inclusion of additional tests in the public services
paying lists and the private paying sources
- Difficulties for the differential diagnosis:
- Occurrence of other infectious conditions that
have differential diagnosis with RA
(Chikungunya fever, Hansen’s disease,
dengue fever, CMV, parvovirus B19, HIV,
viral hepatitis, tuberculosis)
- Frequently limited access to viral serology
and other tests for differential diagnosis
- Broaden the access to additional tests
and image exams eventually necessary
for the differential diagnosis, both on
public and private healthcare services
- Inclusion of possible endemic-epidemic diseases
on Latin America as possible differential
diagnosis for the initial arthritis cases
- Inclusion of the necessary additional tests for
differential diagnosis in the public services paying
lists and the private paying sources
- Non application or non existence of protocols
for treating early RA
- Many of the existing protocols and guidelines,
including the local Latin American associations’
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Discussion
According to Community Oriented Program for Control of
Rheumatic Diseases (COPCORD) methodology, musculo-
skeletal (MSK) complaints in the last 7 days, unrelated to
trauma, are common but vary among different populations
[15]. In LA countries, the prevalence of MSK complaints
was as low as 9.3 % in Guatemala [15–17], 25.5 to 27.1 %
in Mexico [15, 18–20], 26.9 to 30.9 % in Brazil [15, 21, 22],
and as high as 43.9 % in Cuba [15, 23], 45.1 % in Chile [15],
and 46.5 % in Peru [15]. In most studies, a higher prevalence
of pain unrelated to trauma was detected among females [15].
Ideally, patients with recent onset of MSK pain should be
seen by a primary care physician (PCP) (general practition-
er—GP). On the other hand, in the presence of signs or symp-
toms of systemic or inflammatory disease, these patients
should promptly be referred to a rheumatologist. The propor-
tion of rheumatologists that have the opportunity of evaluating
a patient in the first 6 weeks of symptoms has gone from 9 %
in 1997 to 17 % in 2003, although not all of the cases may be
evaluated so quickly [24].
Unfortunately, the early referral to a rheumatologist is not
what usually happens in most, if not all LA countries [25, 26].
This might be due to several reasons:
(1) Most people do not realize that Brheumatism^ is a vague
term that encompasses many diseases with different
treatment and prognosis, so they are not aware that the
first thing they need to do is to have a diagnosis to ex-
plain their MSK condition;
(2) Many people do not have easy access to the healthcare
system, delaying the medical evaluation;
(3) Most patients with MSK pain are referred by the
GP to the specialist without a specific referral
criteria (most patients with common diseases such
as osteoarthritis, fibromyalgia, and mechanical low
back pain should not be referred to a rheumatolo-
gist but followed by a GP);
(4) ManyGP do not readily identify the patients with inflam-
matory conditions delaying the proper referral to the
specialist;
(5) There are few rheumatologists in the secondary or tertia-
ry healthcare system so it usually takes some time for this
specialist’s appointment;
(6) Most, if not all, rheumatology outpatients clinics do not
have a triage system or a Bfast track agenda^ for early
arthritis patients (early arthritis clinic—EAC) so even
those patients need to wait to be seen.
Early recognition and treatment with DMARDs is
important in achieving control of disease and prevention
of joint injury and disability—this strategy is associated
with improved clinical and radiographic outcome. The
first 12 weeks of symptoms, in particular, are a critical
period called as Bvery early RA^ (VERA) and repre-
sents the best chance to achieve a complete remission
and to stop the erosive course of RA [27–29]. Not all
patients meet the criteria for RA at the early stages of
the disease. In clinical practice, all cases of arthritis that
cannot be classified in one of the accepted categories
are referred as Bundifferentiated arthritis^ (UA). In one
third of patients with recent onset arthritis, it is not
possible to come to a definitive diagnosis at presenta-
tion. Among these cases, approximately 30 % will prog-
ress to RA [30]. The others may have alternative defin-
itive diagnoses such as infections, spondyloarthritis, oth-
er systemic rheumatic diseases, microcrystalline arthrop-
athies, osteoarthritis, or others; may also evolve into
remission or even remain as UA [30, 31].
There seems to be, however, a consensus among LA key
opinion leaders rheumatologists about the importance of early
diagnosis for the proper management of RA by rheumatolo-
gists [24–27]. There is evidence of systematic differences be-
tween rheumatologists and non-rheumatologists in early rec-
ognition and in initiating the use of DMARDs for treatment of
RA. Non-rheumatologists generally delay treatment, resulting
Table 2 (continued)
Current reality Challenges Proposed solutions
- Difficulty of access to synthetic and
biological medication
- Dissemination and application of the
existing protocols, or creation of
regional protocols for treating early RA
- Extend the access to synthetic medication
and, when necessary, biological
protocols, already contemplate treatment for
early RA, being necessary a greater dissemination
of those among rheumatologists and correlated
specialists.
- Inclusion of DMARD in the public
services paying lists and the private paying
sources, with emphasis on the importance of early
therapy
- Difficulty to maintain an adequate periodicity
between appointments due to lack of
professionals and vacancies
- Implementation of circumstances that
enable the creation of new vacancies
on existing early arthritis clinics
- Establishment of an effective counter reference
system for discharge of patients followed at early
RA clinics
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in worse outcomes of the disease [32] RA patients were diag-
nosed earlier, receive DMARD therapy more frequently and
achieved better clinical and radiographic outcomes when
managed by rheumatologists [32–35]. To the best clinical
and functional prognosis of patients with RA, it is recom-
mended that the primary care physician refer briefly suspected
cases to the rheumatologist [36]. Despite this, the average time
for the first visit of RA patients with a rheumatologist is 17
and 19 months to elapse before the first administration of
DMARDs [37].
The diagnosis of RA is established considering clinical
findings and complementary examinations. No isolated test,
laboratory, imaging or histopathological, confirms the diagno-
sis alone.
There have also been Bproposed actions^ to increase the
early suspicion, the proper diagnoses of RA, and right and
rapid referral of these patients to the rheumatologists [38].
Among other ideas, it was proposed an adequate training of
general practitioners, general internists, and allied health pro-
fessionals in articular examination and RA symptoms and the
creation of EAC or areas within rheumatology units to provide
care for patients referred early in the course of their disease.
The gap between recognition of symptoms, diagnosis, and
treatment is dependent at least from four steps: from the pa-
tient at symptom onset to assessment in primary care, from
primary care provider (PCP) to rheumatology referral, from
rheumatology referral to assessment and from rheumatology
assessment to commencement of DMARD therapy. Several
strategies have been studied with the aim of reducing the in-
terval between each of these four steps, including the training
of primary care physicians for the early recognition and refer-
ral of suspected cases of RA, self-administered questionnaires,
triage of referrals, triage clinics and early arthritis clinics
(EACs) [39].
Only few studies carried out with Latin American popula-
tions on the demographic and clinical characteristics of pa-
tients diagnosed with ERA can be found in the literature.
GLADAR (Grupo Latino Americano de Estudio de Artritis
Reumatoide) was a large, multicenter, multinational inception
cohort of Latin American patients. Consecutive patients with
ERA (<1 year of disease duration as diagnosed by a rheuma-
tologist) from 46 centers in 14 Latin American countries were
enrolled in GLADAR. Clinical data, laboratory assessments,
and a detailed registry on type of prescription of 1093 patients
were collected at baseline and at 3, 6, 12, 18, and 24months of
follow-up. GLADAR has issued some guidelines for the phar-
macological treatment of RA that promote an early aggressive
therapy. Early disease clinics are established in some LAC
countries. The GLADAR experience has shown that most
early RA patients (i.e., <1 year of disease duration) receive
methotrexate [40–42].
CONAART (Consorcio Argentino de Artritis Temprana—
Argentine Consortium for Early Arthritis) is an initiative of
seven rheumatology centers across Argentina. Patients were
included if they had at least one or more swollen joints and
<2 years of disease duration. A total of 413 patients were
included. From CONAART data, we know some social, de-
mographic, familiar, hereditary, clinical, and laboratory data
from Argentine ERA patients [43]. CONAARTalso informed
about work disability and its main associated factors in pa-
tients with ERA [43]. They also analyzed the effects of ciga-
rette smoking on disease activity, functional capacity, radio-
graphic damage, serology, and presence of extra-articular
manifestations in patients not only with ERA, but also with
undifferentiated arthritis, and found that neither was tobacco
exposure related to the presence of extra-articular manifesta-
tions or to the degree of disability in any of the two groups of
patients [44].
The Brasilia Cohort of RA is an incident cohort of patients
with early RA, followed in the Outpatient Rheumatology
Clinic of Hospital Universitário de Brasília, Universidade de
Brasília. For inclusion in this cohort, early RA is defined as
the occurrence of joint symptoms compatible with pain and
joint swelling with an inflammatory pattern, with or without
morning stiffness or other manifestations suggestive of in-
flammatory joint disease, assessed by a single observer, last-
ing more than 6 weeks and less than 12 months, regardless of
meeting the cri ter ia of the American College of
Rheumatology (ACR). All selected patients retrospectively
met the EULAR/ACR criteria 2010. From the moment of
diagnosis, patients are followed prospectively, and receive
the standard treatment regimen used in Brazil, including syn-
thetic or biological DMARDs, according to their needs.
Patients are monitored in accordance with the principles of
Treat to Target, and the medication adjusted to achieve remis-
sion. Currently, there are 132 patients accompanied by proto-
col form for up to 11 years, from the initial diagnosis. From
Brasilia Cohort, we have information about demographic,
clinical, laboratorial and radiographic characteristics of pa-
tients enrolled in this Brazilian cohort, disease activity, and
impact on quality of life. Other aspects also have been studied
by Brasilia Cohort, including, for example, physical activity
practice among patients with early RA and the possible asso-
ciation between physical activity, disease activity and func-
tional disability, frequency of vaccination, and the orientation
about vaccines among patients in Brasilia Cohort [45–49].
Solutions are needed to offer patients with inflammation of
the small joints—with a high likelihood of having rheumatoid
arthritis—to be seen quickly and receive treatment in a timely
fashion. For early recognition and management of RA, efforts
must be composed mainly of medical education and health
system organization. As a feasible example in LA, a network
for early diagnosis and management of arthritis was imple-
mented adopting several strategies: primary care providers
education, use of referral algorithms, creation of a rapid access
system to an early arthritis clinic (EAC) and institution of a
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task force to reduce the waiting list for rheumatologist assess-
ment. Through an initiative involving Primary and Tertiary
Public Health Care Centers in the South of Brazil, general
practitioners were capacitated to recognize and provide early
referral to patients with arthritis and an EAC was created to
offer prompt evaluation of newly referred patients. The project
was composed by two steps: medical training workshops for
PCPs focused on early recognition and referral of patients
with arthritis and the creation of an EAC for prompt treatment
of newly referred patients. Several workshops for primary care
physicians training were conducted in an University Hospital
in South of Brazil, the Hospital de Clínicas de Porto Alegre
(HCPA). Each workshop lasted 4 h and on each session, three
rheumatologists from HCPA ministered theoretical lesions
which included several themes: concept and etiology of early
UA, importance of early referral to rheumatologist to optimize
outcomes, consequences of RA on function and quality of life,
the algorithm for early referral proposed by the European
League against Rheumatic Diseases (EULAR) [36], the use
of DMARDs, focusing on methotrexate use, and the preven-
tion and management of comorbidities in patients with RA.
Each workshop also included a practical lesson where physi-
cians assessed disease activity in RA by using composite
scores: the Disease Activity Score 28 joints (DAS 28) [50]
and the Clinical Disease Activity Index (CDAI) [51]. Fifteen
students from Medicine School/Federal University of Rio
Grande do Sul (UFRGS) were trained and participated as
monitors during the practical lessons. Physicians participating
in workshops were invited to visit the RA clinic in HCPA to
have contact with RA patients, learning to recognize the pres-
ence of arthritis on physical exam. Additionally, a Clinic for
Assessment and Treatment of Early Arthritis was created in a
Tertiary Health Center (HCPA) after negotiations with the
Municipal Health Office. Since then, four clinical con-
sultations are offered each week for patients with early
arthritis referred from PCPs. Patients referred to this
clinic are seen in a timely fashion (2–4 weeks) because
they are not sent to the usual referral system. The pro-
ject allowed better recognition of patients with early
arthritis and decreased referrals of patients who could
be managed in primary care. The work is ongoing and
was partially funded by PANLAR.
In Mexico, Sánchez et al. described the prevalence of dys-
lipidemia, serum lipid behaviour, and predictors of serum lipid
levels in a cohort of 146 Mexican mestizo ERA patients [52].
Although there are not many publications on early
RA clinics in Latin America, we do know that there
are rheumatology services that maintain clinics with this
purpose. On a survey performed among Latin American
rheumatologists, with an Internet questionnaire sent by
PANLAR, from 214 rheumatologists who responded this
survey, 13.2 and 20.1 %, respectively, informed that
ERA clinics or EARC do exist in their services.
A common pattern for social policies was developed in
most Latin American countries, rooted in a similar develop-
ment model and responsible for some of the most remark-
able features of the relationship between the state and the
society, as well as for incorporating a particular power struc-
ture into a formalized system. The general characteristics of
this pattern were identified in the health sector as: the seg-
mentation and/or exclusion of groups of the population; the
fragmentation of the institutions; the narrow and fragile fi-
nancial basis of the system, mainly based on contributions
upon salaries, and the existence of strong actors with vested
interests represented in this political arena. In spite of these
similarities, it is indispensable to highlight the variations
among the countries, concerning the way they faced this
critical period and the effects of the adjustment policies on
their recovery [53]. Generally, the public health system in
LA countries serves the entire population. In the usual refer-
ral system, general practitioners can refer patients to special-
ists in a hospital setting or specialized outpatient clinic.
Since there are few rheumatologists in the public system,
patients have to wait their turn for the availability of a rheu-
matology consultation. This process takes months and,
sometimes, even years. For patients with RA, this delay
may represent the loss of the window of opportunity for
therapeutic intervention.
On LA, just as in other regions of the world, the costs
related with RA are elevated. Spending on RA patients as-
sume greater impact in developing countries, where financial
resources for health are less robust. This emphasizes the im-
portance of studies assessing the costs and the allocation of
resources. The diagnosis of RA in the initial phase is extreme-
ly important because appropriate treatment early in the disease
can change the natural history of this condition.
The answers to the survey applied to the Latin American
rheumatologists, we conclude that, despite the recognized im-
portance, in LA, not only economic, but also linguistic, cul-
tural, social, and gender barriers can present challenges and
barriers for the healthcare system and its policy for the treat-
ment and health access in the context of ERA.
This gives us a picture of the overall setting in which the
health system reforms are being carried out and how it chang-
es RA care access. We should also add data concerning the
resources for health systems, to have a better representation of
the possibilities and constraints in realizing the health system
reforms, specifically in terms of ERA care policy.
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Appendix 1
Rheumatoid Arthritis in Latin America
1. Section 1. The importance of early diagnosis
1. Is there a specialized early arthritis clinic or rheumatoid arthritis clinic in your service?
(  ) Yes, there is an early rheumatoid arthritis clinic.
(  ) No
(  ) Yes, there is an early arthritis clinic.
Other (specify)
2. If the answer for the irst question was negative, where are patients with early 
rheumatoid arthritis or early arthritis evaluated in your service? 
(  ) In the established rheumatoid arthritis outpatient clinic
(  ) Other (specify)
3. If the answer for the irst question was positive, for how long is there an early arthritis 
clinic or early rheumatoid arthritis clinic? 
(  ) < 1 year 
(  ) Between 1 and 3 years
(  ) Between 3 and 5 years
(  ) Between 5 and 10 years
(  ) More than 10 years
(  ) Other (specify)
4. What is the duration of symptoms to be considered early rheumatoid arthritis in your 
service?
(  ) Less than 12 weeks 
(  ) Less than 1 year
(  ) Less than 2 years
(  ) Less than 3 years
(  ) Less than 5 years
(  ) Other (specify)
5. In your service, is a classiication criterion used to deine patients with early rheumatoid 
arthritis? 
(  ) No, it is considered the clinical diagnosis of arthritis by a physician, regardless of
classiication criteria
(  ) Yes, we use the 1987 ACR classiication criteria
(  ) Yes, we use the 2010 ACR-EULAR classiication criteria
(  ) Other (specify)
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6. How many patients are currently being followed in the early rheumatoid arthritis clinic 
from your service?
(  ) Less than 50 patients
(  ) Between 50 and 100 patients
(  ) Between 100 and 200 patients
(  ) More than 200 patients
(  ) Approximate number if more than 200:
7. How many people are involved in the care of patients in the early rheumatoid arthritis
clinic from your service?
(  ) Teachers
(  ) Rheumatologists doctors
(  ) Residents
(  ) Non-rheumatologist doctors (specify):
(  ) Nurses
(  ) Occupational Therapist
(  ) Secretaries
(  ) Other (specify)
8. How is the access of early rheumatoid arthritis patients to the clinic of your service?
(  ) The demand is free – spontaneous patient demand
(  ) Referral by general practitioner or other specialist
(  ) Referral by rheumatologists
(  ) More than one option
(  ) Other (specify)
9. *What are the main dificulties of access of patients to the early rheumatoid arthritis clinic 
from your service?
10. *What are the main dificulties in diagnosing patients (delay for the irst evaluation, 
dificulties in laboratory tests – specify)
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12. *How is the treatment of patients from the early rheumatoid arthritis clinic of your 
service?
Then specify a speciic protocol
13. Which of the composite indices of disease activity are used in monitoring patients?
(  ) DAS 28
(  ) HAQ
(  ) SDAI
(  ) CDAI
(  ) None
(  ) Other (specify)
14. What quality of life or disability questionnaires are used?
(  ) HAQ
(  ) MHAQ
(  ) RAPID
(  ) Other (specify)
15. Are there dificulties in obtaining medicines for the treatment of patients in the early 
rheumatoid arthritis clinic from your service? Specify:






17. On average, how often a patient is evaluated in the early rheumatoid arthritis clinic of
your service?
(  ) Once a month
(  ) Once every three months
(  ) Once every six months
(  ) Once a year
(  ) Other (specify)
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18. *What is the length of stay of patients in the early rheumatoid arthritis clinic of your 
service? Are they kept untracked in early rheumatoid arthritis clinic or referred to other 
clinics?
19. *What are the main dificulties for the functioning of the early rheumatoid arthritis clinic 
in your service?
20. *What would be the main proposals to improve the functioning of the early rheumatoid 
arthritis clinic in your service?
Rheumatoid Arthritis in Latin America
2. Section 2. Treatment guidelines
1. Are you aware of any rheumatoid arthritis treatment guidelines?
(  ) Yes
(  ) No
If yes, please list the 3 that you know best:
2. Do you use any rheumatoid arthritis treatment guidelines?
(  ) Yes
(  ) No
3. If you answered yes, please indicate which guidelines you use.







5. Which of the following barriers do you face to implement rheumatoid arthritis treatment 
guidelines? You can check more than one option.
(  ) Lack of knowledge about the guidelines
(  ) They are not practical in the management of the individual patient
(  ) They are not updated
s
(  ) Lack of patient access to medications
(  ) I do not agree with the guidelines
(  ) Other (specify)
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3. Section 3. Human resources and health system
1. * Has your National Scientiic Society a census or survey, over the past 5 years, on the 
amount and distribution of rheumatologists?
(  ) Yes
(  ) No
If yes, please indicate date of the census/survey: _ _ / _ _ / _ _ _ _ and how many 
rheumatologists are active: _ _ _ _
2. Are rheumatologists mostly concentrated in big cities (> 100,000)?
(  ) Yes
(  ) No
(  ) I do not know
Comments
3. Are there areas where the population has no access to a rheumatologist or rheumatology
service?
(  ) Yes
(  ) No
Comments
4. Are there public hospitals in 2nd or 3rd level with no rheumatologists?
(  ) Yes
(  ) No
5. Is there public access to rheumatologists or rheumatology services free of charge in public 
hospitals for the entire population?
(  ) Yes
(  ) No
6. Are there formal referral systems for medical or health workers of the 1st level (primary 
health care, PHC) to a rheumatologist or rheumatology service?
(  ) Yes
(  ) No
7. Are there counter-referral systems? (When the patient is formally derived, with its 
diagnosis and treatment, from the rheumatologist or the rheumatology service to the
effectors of the 1st level of care (PHC).)
(  ) Yes
(  ) No
8. Is there postgraduate training for the specialty of rheumatology?
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4. Section 4. Treatments
1. In your country, is there access to the following treatments?











2. Please complete the following table on the cost and the percentage of coverage by health 




% coverage by 
Public Sector(2)
% coverage by 
Social 
Security(2)
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Tofacitinib
(1): 0–500; 501-1000; 1001-1500; 1501-2000; >2000
(2): 0-10%; 11-20%; 21-30%; 31-40%; 41-50%; 51-60%; 61-70%; 71-80%; 81-90%; 91-
100%
Comments
3. How would you rate the dificulty (0-10) for the prescription of these drugs in the 
following health systems? (Where 0 is no dificulty and 10 is impossible to prescribe.)












4. Do you think that rheumatologists mostly exercise the “Treat to Target” and “Tight 
Control” to achieve remission of the disease?
(  ) Yes
(  ) No
Comments
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